---
title: "Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286968612.md"
description: "Charles River Laboratories International Inc. (CRL) shares rose 1.67% to $152.43, breaking a four-day losing streak, despite a poor overall market day. The S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. CRL's stock remains 33.40% below its 52-week high of $228.88. Competitors had mixed results, with Labcorp down 0.74% and Alnylam Pharmaceuticals and Bio-Techne rising 2.81% and 2.34%, respectively."
datetime: "2026-05-19T21:17:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286968612.md)
  - [en](https://longbridge.com/en/news/286968612.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286968612.md)
---

# Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Charles River Laboratories International Inc. (CRL) rallied 1.67% to $152.43 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.67% to 7,353.61 and Dow Jones Industrial Average falling 0.65% to 49,363.88.

The stock's rise snapped a four-day losing streak.

Charles River Laboratories International Inc. closed 33.40% below its 52-week high of $228.88, which the company reached on January 13th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Labcorp Holdings Inc. (LH) fell 0.74% to $253.69, Alnylam Pharmaceuticals Inc. (ALNY) rose 2.81% to $294.30, and Bio-Techne Corp. (TECH) rose 2.34% to $45.47.

Trading volume (1.1 M) eclipsed its 50-day average volume of 878,841.

Data source: Dow Jones Market Data, FactSet. Data compiled May 19, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-19-26 1717ET

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [LH.US](https://longbridge.com/en/quote/LH.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Cyber Threats Loom Over Charles River Laboratories: Rising AI-Enabled Attacks, Third-Party Risks, and Potential Financial Fallout](https://longbridge.com/en/news/285801360.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)